All In Biotech

Drug Trial Radar · NCT07791537

Phase 2 Study to Evaluate the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial Assessing the Efficacy and Safety of MWN109 Injection in Non-Diabetic Participants With Overweight or Obesity

Last checked: Nov 20, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 125 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

125

Actual

Start

Dec 26, 2025

Primary completion

Oct 2026

Study completion Nov 2026

Sponsor

Sponsor type
Industry
First posted
Aug 28, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter, randomized, double-blind, placebo-controlled phase II study conducted in China. It aims to evaluate the efficacy and safety of MWN109 injection in non-diabetic overweight or obese participants. A total of 125 participants were enrolled in the study. All participants were randomly assigned using stratified block randomization by gender (male or female) and allocated to 4 treatment groups at a 1:1:1:1 ratio, with approximately 30 participants in each group. Each treatment group will reach the target dose through dose titration. This study consists of a screening period of up to 2 weeks, a treatment period of 36 weeks, and a follow-up period of 4 weeks, totaling 42 weeks. The primary endpoint is the percentage change in body weight compared to the baseline after 36 weeks of drug administration. The secondary endpoints include the proportions of participants with a body weight reduction of ≥5%, ≥10%, ≥15%, and ≥20% relative to the baseline after 36 weeks of treatment, as well as the change in waist circumference relative to the baseline.

Conditions

  • Overweight , Obesity

Interventions

  • MWN109 1Drug

    Administered SC, QW, 36 weeks

  • MWN109 2Drug

    Administered SC, QW, 36 weeks

  • MWN109 3Drug

    Administered SC, QW, 36 weeks

  • PlaceboDrug

    Administered SC, QW, 36 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage change in body weight compared to baseline after 36 weeks of drug administrationTime frame: Baseline, Week 36

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.